Published in Am J Gastroenterol on May 10, 2011
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev (2012) 1.82
ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol (2015) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.52
Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol (2013) 1.18
Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol (2014) 1.16
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol (2014) 0.88
Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep (2014) 0.88
Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int (2013) 0.87
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol (2012) 0.86
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Dig Dis (2015) 0.83
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am (2014) 0.82
Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci (2013) 0.82
Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci (2014) 0.81
Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis (2013) 0.81
Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? World J Gastroenterol (2014) 0.80
Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res (2015) 0.79
Overlap syndromes: an emerging diagnostic and therapeutic challenge. Saudi J Gastroenterol (2014) 0.78
Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol (2016) 0.77
Risks of using ursodeoxycholic acid to treat primary sclerosing cholangitis. Gastroenterology (2011) 0.77
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. Orphanet J Rare Dis (2013) 0.77
Thiopurine S-methyltransferase (TPMT) activity is better determined by biochemical assay versus genotyping in the Jewish population. Dig Dis Sci (2014) 0.77
Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol (2014) 0.76
In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. Dig Dis Sci (2011) 0.76
The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study. Medicine (Baltimore) (2016) 0.76
Chemoprevention of colorectal cancer. Dig Dis (2014) 0.76
Controversies in the management of primary sclerosing cholangitis. World J Hepatol (2016) 0.76
Circulating CD4+CD25+ regulatory T cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis. Dig Dis Sci (2013) 0.76
Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75
Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol (2017) 0.75
Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr (2015) 0.75
Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol (2016) 0.75
A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis (2016) 0.75
Recent developments in the management of idiopathic cholestatic liver disease. Ann Gastroenterol (2012) 0.75
Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis. Nat Rev Gastroenterol Hepatol (2011) 0.75
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res (2005) 2.64
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol (2001) 2.61
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med (1997) 2.41
Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology (1999) 2.25
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology (1999) 2.20
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Role of bile acids in colorectal carcinogenesis. Eur J Cancer (1995) 1.66
Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol (2009) 1.63
Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis (2006) 1.50
Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther (2007) 1.35
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology (2001) 1.31
The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol (2002) 1.30
Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene (2002) 1.22
Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am (1999) 1.19
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr (2004) 1.16
The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther (2005) 1.13
Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer (2008) 1.04
The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol (1997) 1.00
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology (2010) 0.98
Metabolism of ursodeoxycholic acid in man. Gastroenterology (1977) 0.97
Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res (1995) 0.94
Characteristics of apoptosis in HCT116 colon cancer cells induced by deoxycholic acid. J Biochem (2005) 0.93
Bile acids reduce the apoptosis-inducing effects of sodium butyrate on human colon adenoma (AA/C1) cells: implications for colon carcinogenesis. Biochem Biophys Res Commun (2000) 0.91
Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology (1992) 0.89
Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett (2009) 0.87
Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res (1998) 0.87
Requirements for induction of DNA strand breaks by lithocholic acid. Cancer Res (1982) 0.86
The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology (1995) 0.85
Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved? Free Radic Res (1997) 0.85
Conversion of 7-ketolithocholic acid to ursodeoxycholic acid by human intestinal anaerobic microorganisms: interchangeability of chenodeoxycholic acid and ursodeoxycholic acid. Gastroenterol Jpn (1979) 0.81
Effects of diet on the fecal excretion and bacterial modification of acidic and neutral steroids, and implications for colon carcinogenesis. Cancer Res (1981) 0.80
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Management of ingested foreign bodies and food impactions. Gastrointest Endosc (2011) 6.08
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol (2007) 3.14
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc (2009) 2.84
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Sedation and anesthesia in GI endoscopy. Gastrointest Endosc (2008) 2.73
The role of endoscopy in the management of obscure GI bleeding. Gastrointest Endosc (2010) 2.68
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc (2008) 2.37
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. Gastrointest Endosc (2012) 2.22
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc (2006) 2.14
The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc (2010) 2.11
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc (2008) 2.08
Infection control during GI endoscopy. Gastrointest Endosc (2008) 2.07
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Utility of double-balloon colonoscopy for completion of colon examination after incomplete colonoscopy with conventional colonoscope. Gastrointest Endosc (2007) 1.91
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Double-balloon enteroscopy and capsule endoscopy have comparable diagnostic yield in small-bowel disease: a meta-analysis. Clin Gastroenterol Hepatol (2008) 1.81
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol (2010) 1.67
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum. Am J Physiol Gastrointest Liver Physiol (2005) 1.63
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl (2006) 1.59
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Predictive value of actin-free Gc-globulin in acute liver failure. Liver Transpl (2007) 1.55
Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res (2011) 1.54
Comparison of the yield and miss rate of narrow band imaging and white light endoscopy in patients undergoing screening or surveillance colonoscopy: a meta-analysis. Am J Gastroenterol (2011) 1.53
Comparison of single- versus double-balloon assisted-colonoscopy for colon examination after previous incomplete standard colonoscopy. Dig Dis Sci (2012) 1.52
Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol (2007) 1.51
Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2013) 1.50
Training in small-bowel capsule endoscopy: assessing and defining competency. Gastrointest Endosc (2013) 1.50